Literature DB >> 10856684

BIOPLAN: software for the biological evaluation of. Radiotherapy treatment plans.

B Sanchez-Nieto1, A E Nahum.   

Abstract

Distributions of absorbed dose do not provide information on the biological response of tissues (either tumor or organs at risk [OAR]) to irradiation. BIOPLAN (BiOlogical evaluation of PLANs) has been conceived and developed as a PC-based user-friendly software that allows the user to evaluate a treatment plan from the (more objective) point of view of the biological response of the irradiated tissues, and at the same time, provides flexibility in the use of models and parameters. It requires information on dose-volume histograms (DVHs) and can accept a number of different formats (including DVH files from commercial treatment planning systems). BIOPLAN provides a variety of tools, such as tumor control probability (TCP) calculations (using the Poisson model), normal tissue complication probability (NTCP) calculations (using either the Lyman-Kutcher-Burman or the relative seriality models), the ATCP method, DVH subtraction, plots of NTCP/TCP as a function of prescription dose, tumor and OAR dose statistics, equivalent uniform dose (EUD), individualized dose prescription, and parametric sensitivity analysis of the TCP/NTCP models employed.

Entities:  

Mesh:

Year:  2000        PMID: 10856684     DOI: 10.1016/s0958-3947(00)00031-5

Source DB:  PubMed          Journal:  Med Dosim        ISSN: 1873-4022            Impact factor:   1.482


  27 in total

1.  Dosimetric and radiobiological comparison of helical tomotherapy, forward-planned intensity-modulated radiotherapy and two-phase conformal plans for radical radiotherapy treatment of head and neck squamous cell carcinomas.

Authors:  S Chatterjee; N Willis; S M Locks; J H Mott; C G Kelly
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

2.  Objective assessment of image quality VI: imaging in radiation therapy.

Authors:  Harrison H Barrett; Matthew A Kupinski; Stefan Müeller; Howard J Halpern; John C Morris; Roisin Dwyer
Journal:  Phys Med Biol       Date:  2013-11-21       Impact factor: 3.609

3.  The effect of 6 and 15 MV on intensity-modulated radiation therapy prostate cancer treatment: plan evaluation, tumour control probability and normal tissue complication probability analysis, and the theoretical risk of secondary induced malignancies.

Authors:  M Hussein; S Aldridge; T Guerrero Urbano; A Nisbet
Journal:  Br J Radiol       Date:  2011-10-18       Impact factor: 3.039

4.  Analysis of outcomes in radiation oncology: an integrated computational platform.

Authors:  Dezhi Liu; Munther Ajlouni; Jian-Yue Jin; Samuel Ryu; Farzan Siddiqui; Anushka Patel; Benjamin Movsas; Indrin J Chetty
Journal:  Med Phys       Date:  2009-05       Impact factor: 4.071

5.  A framework for implementation of organ effect models in TOPAS with benchmarks extended to proton therapy.

Authors:  J Ramos-Méndez; J Perl; J Schümann; J Shin; H Paganetti; B Faddegon
Journal:  Phys Med Biol       Date:  2015-06-10       Impact factor: 3.609

6.  Objective assessment of the effects of tumor motion in radiation therapy.

Authors:  Yijun Ding; Harrison H Barrett; Matthew A Kupinski; Yevgeniy Vinogradskiy; Moyed Miften; Bernard L Jones
Journal:  Med Phys       Date:  2019-06-07       Impact factor: 4.071

7.  On the Inclusion of Short-distance Bystander Effects into a Logistic Tumor Control Probability Model.

Authors:  David G Tempel; N Patrik Brodin; Wolfgang A Tomé
Journal:  Cureus       Date:  2018-01-01

8.  Optimization of radiotherapy fractionation schedules based on radiobiological functions.

Authors:  Fernando Pizarro; Araceli Hernández
Journal:  Br J Radiol       Date:  2017-08-22       Impact factor: 3.039

9.  Radiobiologically guided optimisation of the prescription dose and fractionation scheme in radiotherapy using BioSuite.

Authors:  J Uzan; A E Nahum
Journal:  Br J Radiol       Date:  2012-03-28       Impact factor: 3.039

10.  A genetic algorithm for variable selection in logistic regression analysis of radiotherapy treatment outcomes.

Authors:  Olivier Gayou; Shiva K Das; Su-Min Zhou; Lawrence B Marks; David S Parda; Moyed Miften
Journal:  Med Phys       Date:  2008-12       Impact factor: 4.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.